Not an expert, not a doctor, etc. My barely informed interpretation and resulting take here is that: 1) This really only shows any efficacy when given shortly

Not an expert, not a doctor, etc. My barely informed interpretation and resulting take here is that: 1) This really only shows any efficacy when given shortly after the onset of symptoms 2) Remdesivir is an expensive and IV only drug that is difficult to produce in high quantities 3) The combination of the above makes this not particularly useful for treating the general population - we do not want everyone that shows mild symptoms to be rushing to the doctor for a treatment that has to be provided by a professional, and by the time we know if the symptoms will be severe and life threatening it is too late for remdesivir to be useful 4) That would seem to make it most useful for people that have known risk factors and co-morbidities to be candidates for remdesivir use. I do not know if the results are similarly promising for people that have those criteria, however. If these results hold up it's good news, but I don't know if it's great news - it seems like the factors involved here make it impractical for the large scale treatment of cv19